Bristol-Myers Squibb Company (BMY) Board Elects Charles Bancroft Chief Financial Officer

Bristol-Myers Squibb Company (BMY) Board Elects Charles Bancroft Chief Financial Officer


NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the company's Board of Directors has elected Charles Bancroft chief financial officer effective April 8, 2010. In this role, Mr. Bancroft will be responsible for directing and managing the company's fiscal operations and the global finance organization. Mr. Bancroft has been serving as the company's acting CFO since January 1, 2010. He will report to Lamberto Andreotti, president and chief operating officer, and chief executive officer designate.

"The Board of Directors, Jim Cornelius and I have great confidence in Charlie's ability to provide the financial stewardship needed to help drive shareholder value," said Mr. Andreotti. "His tenure with Bristol-Myers Squibb has been marked by strong leadership and depth of experience in finance, earning him trust and respect from his peers across all functions and within the entire finance organization."

Mr. Bancroft joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

Contact:

Bristol-Myers Squibb Company Media: Tracy Furey, 609-252-3208 [email protected] or Investors: John Elicker, 609-252-4611 [email protected]
 
 
 

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.